Gregory Ciongoli
Patrimonio netto: 16 M $ in data 31/08/2026
Patrimonio netto: 16 M $ in data 31/08/2026
Gregory A. Ciongoli is the founder of Adiumentum Capital Management LLC.
Mr. Ciongoli is Chairman at Atara Biotherapeutics, Inc. starting in 2025.
Mr. Ciongoli is Director at Zymeworks, Inc. starting in 2025.
Mr. Ciongoli is Independent Director at REGENXBIO, Inc. starting in 2026.
Mr. Ciongoli was Partner at The Baupost Group LLC.
Mr. Ciongoli earned an MBA from Harvard Business School.
Mr. Ciongoli completed undergraduate studies at Woodrow Wilson School of Public & International Affairs.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
ZYMEWORKS INC. 0,7% | 12/01/2026 | 493.500 ( 0,7% ) | 15 M $ | 31/08/2026 |
REGENXBIO, INC. 0,18% | 27/08/2026 | 118.035 ( 0,18% ) | 1 M $ | 31/08/2026 |
| 09/06/2026 | 12.000 ( 0,12% ) | 106 800 $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Presidente | 03/09/2025 |
| ZYMEWORKS INC. | Direttore/Membro del Consiglio | 11/08/2025 |
| REGENXBIO INC. | Direttore/Membro del Consiglio | 25/08/2026 |
| GOSSAMER BIO, INC. | Direttore/Membro del Consiglio | 16/09/2026 |
| Società | Posizione | Fine |
|---|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 7 |
|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Finance |
REGENXBIO, Inc.
REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Woodrow Wilson School of Public & International Affairs
Woodrow Wilson School of Public & International Affairs Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gossamer Bio, Inc.
Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Zymeworks, Inc.
Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale